Impact of platelet-rich plasma on an ovary in cases of poor ovarian function

Evaluation of the effect of platelet-rich plasma injection in an ovary in cases of poor ovarian function (poor response)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210828052310N1

Enrollment

Registered

2021-10-02

Start date

2021-10-19

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poor Ovarian Response. Female infertility

Interventions

Intervention 1: Intervention group: 12 patients with poor ovarian function referred to Valiasr Infertility Clinic will participate in the study during the year 1400. The ovulation stimulation is don

4 ccs of platelet-rich plasma is injected at four points of the ovary under anesthesia by the infertility unit. Intervention 2: Control group: On the opposite side of the ovary, the same twelve patien

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: History of less than 3 eggs per cycle Antimullerian hormone less than 0.5 Antral follicles less than 5 Existence of 10 million sperm in sperm analysis At least three percent of normal sperm morphology

Exclusion criteria

Exclusion criteria: Immunological diseases of patients Hematologic disease Chromosomal or genetic disorder Hemoglobin level less than 11 grams per deciliter and platelets less than one hundred and fifty thousand per cubic millimeter Systemic use of corticosteroids within two weeks before the procedure Absence of underlying disease of infertile women No contraindications for pregnancy Uterine disorders Submucosal myoma Asherman syndrome

Design outcomes

Primary

Measure	Time frame
Number of Oocyte in the first and second cycles. Timepoint: The oocyte retrieval day. Method of measurement: Based on embryologist assessment.;Number of mature oocyte. Timepoint: The oocyte retrieval day in the first and second cycles. Method of measurement: Based on embryologist assessment.;Anti Mullerian Hormone level. Timepoint: The second day of cycles 1 and 2. Method of measurement: Blood test.;Follicle Stimulating Hormone level. Timepoint: The second day of cycles 1 and 2. Method of measurement: Blood test.	—

Measure

Time frame

Number of Oocyte in the first and second cycles. Timepoint: The oocyte retrieval day. Method of measurement: Based on embryologist assessment.;Number of mature oocyte. Timepoint: The oocyte retrieval day in the first and second cycles. Method of measurement: Based on embryologist assessment.;Anti Mullerian Hormone level. Timepoint: The second day of cycles 1 and 2. Method of measurement: Blood test.;Follicle Stimulating Hormone level. Timepoint: The second day of cycles 1 and 2. Method of measurement: Blood test.

—

Secondary

Measure	Time frame
Number of Embryo. Timepoint: Three to six days after fertilization. Method of measurement: Based on the opinion of the embryologist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeide Shahsavari

Bandare-abbas University of Medical Sciences

saiede.shahsavari@yahoo.com+98 76 3333 3280

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026